TTR.
Infrastructure
- Reports this week
- 0
- Active events
- 0
- Connections
- 15
What's happening
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around TTR this week
News at the entities that move TTR most-
Nasdaq StructuralGolub Capital BDC, Inc. listed on the electronic stock exchange.Moves TTR
Connections
The 6 strongest of 15, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Hoffmann-La Roche Transactional
Hoffmann-La Roche is evaluating TTR's prasinezumab and has recognized a milestone payment from TTR.
-
Nasdaq Structural
TTR functions as an infrastructure company whose business operations are dependent on the existence and functionality of the Nasdaq market platform.
-
Munich Shared context
TTR's findings are discussed and presented within the context of the European Society of Cardiology Congress held in Munich.
-
Ionis Pharmaceuticals Structural
Ionis Pharmaceuticals is focused on developing therapeutic agents that specifically target the TTR protein.
-
Novo Nordisk Operational
Novo Nordisk is actively evaluating therapeutic strategies targeting the TTR protein associated with ATTR amyloidosis.
-
Bristol-Myers Squibb Operational
Bristol-Myers Squibb is evaluating TTR's drug candidate, moponetug, for Alzheimer's disease.